Tevogen Bio Holdings

Tevogen Bio is a clinical-stage biotechnology company specializing in the development of off-the-shelf, genetically unmodified precision T cell therapies. The company's proprietary ExCellerator platform aims to provide scalable and cost-effective treatments for infectious diseases, cancers, and neurological disorders by leveraging the natural potency of CD8+ cytotoxic T lymphocytes. Its lead candidate, TVGN-489, is being developed for high-risk COVID-19 patients and has demonstrated a strong safety profile in clinical trials. Tevogen Bio focuses on addressing significant unmet medical needs through personalized immune responses delivered as standardized products. The company is headquartered in New Jersey and is publicly traded on the Nasdaq.